Novavax, Inc. has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid in Japan include an upfront payment, payment related to the 2024/2025 season, annual milestones associated with regulatory approvals and royalties on net sales earned every season moving forward.
""Our ongoing partnership with Takeda is important for Novavax and our strengthened agreement enhances our ability to operate effectively in the Japanese market,"" said John C. Jacobs, president and chief executive officer, Novavax. ""This partnership further validates our cutting-edge technology platform and proprietary Matrix-M adjuvant and our efforts to become a partner of choice.""
Novavax, Inc. tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, including protein-based nanoparticles and its Matrix-M adjuvant.